Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2011 Feb 15;203(4):473-8.
doi: 10.1093/infdis/jiq077. Epub 2011 Jan 13.

A therapeutic dendritic cell-based vaccine for HIV-1 infection

Felipe García  1 , Núria Climent, Lambert Assoumou, Cristina Gil, Nuria González, José Alcamí, Agathe León, Joan Romeu, Judith Dalmau, Javier Martínez-Picado, Jeff Lifson, Brigitte Autran, Dominique Costagliola, Bonaventura Clotet, Josep M Gatell, Montserrat Plana, Teresa Gallart; DCV2/MANON07- AIDS Vaccine Research Objective Study Group
Affiliations
Randomized Controlled Trial

A therapeutic dendritic cell-based vaccine for HIV-1 infection

Felipe García et al. J Infect Dis. .

Abstract

A double-blinded, controlled study of vaccination of untreated patients with chronic human immunodeficiency virus type 1 (HIV-1) infection with 3 doses of autologous monocyte-derived dendritic cells (MD-DCs) pulsed with heat inactivated autologous HIV-1 was performed. Therapeutic vaccinations were feasible, safe, and well tolerated. At week 24 after first vaccination (primary end point), a modest significant decrease in plasma viral load was observed in vaccine recipients, compared with control subjects (P = .03). In addition, the change in plasma viral load after vaccination tended to be inversely associated with the increase in HIV-specific T cell responses in vaccinated patients but tended to be directly correlated with HIV-specific T cell responses in control subjects.

Trial registration: ClinicalTrials.gov NCT00402142.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Change in plasma viral load from baseline during the study period. A, Median values. B, Individual values. Arrows represent vaccinations. Numbers at bottom represent patients at risk. P values of Mann-Whitney U test are shown at weeks 16, 24, and 48. P value of area under the curve (AUC) is also shown.
Figrue 2.
Figrue 2.
Correlation between the median change in the HIV-1-specific T cell responses with the median change in plasma viral load in patients in the DC-HIV-1 group and DC-control recipients during the study period. Each dot represents a time point.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kundu SK, Engleman E, Benike C, et al. A pilot clinical trial of HIV antigen-pulsed allogeneic and autologous dendritic cell therapy in HIV-infected patients. AIDS Res Hum Retroviruses. 1998;14:551–60. - PubMed
    1. Lu W, Arraes L, Ferreira W, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004;10:1359–65. - PubMed
    1. García F, Lejeune M, Climent N, et al. Therapeutic immunization with dendritic cells loaded with inactivated autologous HIV-1 in chronic HIV-1 infected patients. J Infect Dis. 2005;195:1680–5. - PubMed
    1. Ide F, Nakamura T, Tomizawa M, et al. Peptide-loaded dendritic-cell vaccination followed by treatment interruption for chronic HIV-1 infection: a phase 1 trial. J Med Virol. 2006;78:711–8. - PubMed
    1. Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol. 2008;15:284–92. - PMC - PubMed

Publication types

MeSH terms

Associated data